Free to follow every thread. No paywall, no dead ends.
Lung cancer: the story on HearLore | HearLore
Lung cancer
In 1919, an entire medical school class at Washington University was summoned to witness a single autopsy of a man who had died from lung cancer, and the attending surgeon, Alton Ochsner, warned them they might never see such a case again. At that time, lung cancer was considered among the rarest forms of disease, with only 374 cases tabulated in medical literature by 1912. Today, the landscape has shifted dramatically, with 2.2 million new cases diagnosed globally in 2020 alone, resulting in 1.8 million deaths. This transformation from a medical curiosity to the leading cause of cancer death worldwide is inextricably linked to the rise of cigarette smoking in the 20th century. Before the mass production of cigarettes, lung cancer was so uncommon that doctors rarely encountered it, but the subsequent decades saw a surge in cases that mirrored the consumption patterns of tobacco products. The disease now strikes with a median age of 70, and the average age at death is 72, making it a condition that predominantly affects the elderly, yet it remains rare in those younger than 40. The sheer scale of this epidemic has forced a global reckoning with how industrial habits and environmental exposures can alter human biology on a massive scale.
The Smoking Gun
Tobacco smoking is responsible for 80 to 90 percent of all lung cancer cases, a causal link that was established through decades of rigorous scientific inquiry and public relations battles. In the 1940s and early 1950s, case-control studies began to show that people with lung cancer were significantly more likely to have smoked cigarettes than those without the disease. This evidence culminated in the 1954 British Doctors Study, which provided the first major prospective cohort data linking tobacco use to the disease. The scientific consensus became undeniable, yet the tobacco industry fought back with calculated deception. In December 1953, CEOs of six major American tobacco companies hired the public relations firm Hill & Knowlton to craft a strategy that would cast doubt on the emerging science. They funded tobacco-friendly research, declared the link to lung cancer controversial, and demanded endless more studies to settle the purported controversy, all while their own internal research confirmed the danger. This campaign included a full-page advertisement titled A Frank Statement to Cigarette Smokers, which ran in newspapers nationwide in January 1954, attempting to distract the public from the accumulating evidence. Despite these efforts, the United Kingdom's Royal College of Physicians officially concluded in 1962 that cigarette smoking causes lung cancer, prompting the United States Surgeon General to empanel an advisory committee. The committee's report, published in January 1964, firmly concluded that cigarette smoking far outweighs all other factors in causing lung cancer, marking a turning point in public recognition of the disease's origins.
What was the number of lung cancer cases tabulated in medical literature by 1912?
Only 374 cases of lung cancer were tabulated in medical literature by 1912. This low number reflected the rarity of the disease before the mass production of cigarettes in the 20th century.
When did the United States Surgeon General conclude that cigarette smoking causes lung cancer?
The United States Surgeon General published a report in January 1964 that concluded cigarette smoking far outweighs all other factors in causing lung cancer. This report followed the 1962 conclusion by the United Kingdom's Royal College of Physicians.
What percentage of lung cancer cases are caused by radon exposure?
Radon exposure is responsible for between 3 and 14 percent of lung cancer cases. This risk increases significantly when combined with cigarette smoking due to a synergistic effect.
What is the five-year survival rate for stage IA1 lung cancer?
The five-year survival rate for stage IA1 lung cancer is 92 percent. This stage represents the earliest TNM stage where cancer is limited to smaller tumors.
How much funding was spent on lung cancer research per US death in 2022?
Around 3,200 US dollars was spent on lung cancer research per US death in 2022. This amount is considerably lower than the funding per death for brain cancer or breast cancer.
While tobacco smoke is the primary driver of lung cancer, it is not the only invisible threat lurking in the environment. Radon gas, a naturally occurring breakdown product of the Earth's radioactive elements, has been recognized as a cause of lung cancer since the late 19th century, when miners in Germany's Ore Mountains developed a deadly disease known as mountain sickness. By 1938, up to 80 percent of miners in affected regions died from this disease, which was later identified as lung cancer. In the 1950s, radon and its breakdown products were established as causes of lung cancer in miners, and by 1988, the International Agency for Research on Cancer classified radon as carcinogenic to humans. Radon exposure is responsible for between 3 and 14 percent of lung cancer cases, and its presence in residential spaces can increase occupants' risk, particularly when combined with cigarette smoking. The synergistic effect of smoking and radon exposure means that the risk of someone who smokes and has radon exposure dying from lung cancer is much higher than would be expected from adding the two risks together. Other occupational hazards also play a significant role, with exposure to asbestos, arsenic, chromium, nickel, and diesel exhaust contributing to 9 to 15 percent of lung cancer cases. These chemicals cause lung cancer either directly or indirectly by inflaming the lung, and the risk increases with the duration of exposure. The intersection of these environmental factors with genetic susceptibility creates a complex web of risk that extends far beyond the individual choices of the smoker.
The Body Betrays
Lung cancer often presents no symptoms in its early stages, making it a silent killer that can only be detected through medical imaging. When symptoms do arise, they are frequently nonspecific respiratory problems such as coughing, shortness of breath, or chest pain, which can differ from person to person. Around one in four people cough up blood, ranging from small streaks in the sputum to large amounts, while around half of those diagnosed experience shortness of breath. Other symptoms depend on the location and size of the tumor, with tumors in the thorax causing breathing problems by obstructing the trachea or disrupting the nerve to the diaphragm. Some patients experience difficulty swallowing by compressing the esophagus, hoarseness by disrupting the nerves of the larynx, or Horner's syndrome by disrupting the sympathetic nervous system. Horner's syndrome is also common in tumors at the top of the lung, known as Pancoast tumors, which also cause shoulder pain that radiates down the little-finger side of the arm as well as destruction of the topmost ribs. Beyond the lungs, about one in three people diagnosed with lung cancer have symptoms caused by metastases in sites other than the lungs. Brain metastases can cause headache, nausea, vomiting, seizures, and neurological deficits, while bone metastases can cause pain, bone fractures, and compression of the spinal cord. The disease can also release body-altering hormones, causing unusual symptoms called paraneoplastic syndromes, such as hypercalcemia, which manifests as nausea, vomiting, abdominal pain, constipation, increased thirst, frequent urination, and altered mental status.
A Race Against Time
The diagnosis of lung cancer requires a definitive biopsy of the suspected tissue to be histologically examined for cancer cells, often obtained through minimally invasive techniques such as a fiberoptic bronchoscope or fine needle aspiration. Imaging tests, including chest X-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, are used to evaluate the presence, extent, and location of tumors. The staging of lung cancer is a critical assessment of the degree of spread, using the Tumor, Node, Metastasis (TNM) system to score the size and extent of the tumor, spread to regional lymph nodes, and distant metastases. Cancer limited to smaller tumors is designated stage I, while disease with larger tumors or spread to the nearest lymph nodes is stage II. Cancer with the largest tumors or extensive lymph node spread is stage III, and cancer that has metastasized is stage IV. The prognosis varies significantly based on the stage of the disease at diagnosis, with those diagnosed at the earliest TNM stage, IA1, having a five-year survival of 92 percent, while those diagnosed at the most advanced stage, IVB, have a five-year survival of 0 percent. Small-cell lung cancer, which accounts for 15 percent of cases, is particularly aggressive, with only 10 to 15 percent of people surviving five years after diagnosis. The average person diagnosed with limited-stage small-cell lung cancer survives 12 to 20 months from diagnosis, while with extensive-stage small-cell lung cancer, the average survival is around 12 months.
The Battle for Survival
Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the person's health, with common treatments including surgical removal of the tumor, chemotherapy, and radiation therapy. For early-stage non-small-cell lung cancer, the first line of treatment is often surgical removal of the affected lobe of the lung, while for those not well enough to tolerate full lobe removal, a smaller chunk of lung tissue can be removed by wedge resection or segmentectomy surgery. For later-stage cancer, chemotherapy and radiation therapy are combined with newer targeted molecular therapies and immune checkpoint inhibitors. Up to 30 percent of tumors have mutations in the EGFR gene that result in an overactive EGFR protein, which can be treated with EGFR inhibitors such as osimertinib, erlotinib, gefitinib, afatinib, or dacomitinib. Up to 7 percent of those with non-small-cell lung cancer harbor mutations that result in hyperactive ALK protein, which can be treated with ALK inhibitors such as crizotinib, alectinib, brigatinib, and ceritinib. Despite these advances, the five-year survival rate for all lung cancer patients remains around 19 percent, with survival rates higher in women, those diagnosed at an earlier stage, and those diagnosed at a younger age. The integration of palliative care from the time of diagnosis improves the survival time and quality of life of those with lung cancer, managing symptoms such as shortness of breath and pain, which are reported by up to 92 percent of patients.
The Cost of Silence
Despite being the deadliest type of cancer, lung cancer receives the third-most funding from the US National Cancer Institute, behind brain cancers and breast cancer. In 2022, around $3,200 was spent on lung cancer research per US death, considerably lower than that for brain cancer ($22,000 per death), breast cancer ($14,000 per death), and cancer as a whole ($11,000 per death). This disparity in funding reflects a historical neglect of the disease, which has been stigmatized due to its association with smoking. The uncertainty of lung cancer prognosis often causes stress and makes future planning difficult for those with lung cancer and their families. Those whose cancer goes into remission often experience fear of their cancer returning or progressing, associated with poor quality of life, negative mood, and functional impairment. This fear is exacerbated by frequent or prolonged surveillance imaging and other reminders of cancer risks. The global incidence of lung cancer is expected to rise to nearly 3 million annual deaths by 2035, due to high rates of tobacco use and aging populations. Lung cancer deaths are expected to rise globally to nearly 3 million annual deaths by 2035, due to high rates of tobacco use and aging populations. The disparity in funding and the stigma surrounding the disease have created a challenging landscape for research and treatment, with nearly 2,250 active clinical trials registered as of 2021, yet the per-death funding remains significantly lower than for other cancers.